A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
A phase 3 trial of Pegylated liposomal doxorubicin, Paclitaxel / nab-paclitaxel, Letrozole in ovarian cancer, run by Verastem, Inc., now recruiting.
Overview
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer is a phase 3 interventional study registered as NCT06072781 by Verastem, Inc., with 270 participants planned, started 2024-03-18 and due to reach its primary completion in 2028-10-15. Interventions recorded: avutometinib, Defactinib, Pegylated liposomal doxorubicin, Paclitaxel, Letrozole. Conditions listed: Low Grade Serous Ovarian Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients
Shares Verastem Oncology, Ovarian cancer.
- TrialStudy of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer
- TrialStudy to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer
Shares Pegylated liposomal doxorubicin, Paclitaxel / nab-paclitaxel, Ovarian cancer.
- TrialAn Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Can
Shares Pegylated liposomal doxorubicin, Paclitaxel / nab-paclitaxel, Ovarian cancer.
- TrialA Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.
- TrialIN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurren
- TrialCATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ov
- TrialOncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b)